US approval status and milestone tracker

Retatrutide is not approved. This page lists what has happened, what the sponsor has said it plans, and what nobody has announced.

  1. Phase 2Published Aug 2023
  2. Phase 34 trials reported, Dec 2025 to Jul 2026
  3. SubmissionLilly plans Q1 2027. Not made yet.
  4. FDA reviewNo date exists
  5. ApprovalUnknown

This page covers the whole road, from the phase 2 paper to an FDA decision that has no date.

Short answer (2026-11-19): not FDA approved. No regulatory submission reported yet. Lilly's stated plan is a US submission in Q1 2027. No FDA decision date exists.

Dated milestones

  1. Phase 2 obesity trial published

    Jastreboff et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial," N Engl J Med 389(6):514-526. DOI 10.1056/NEJMoa2301972. Peer reviewed Funded by Eli Lilly.

  2. First phase 3 topline (TRIUMPH-4)

    Lilly announced results in adults with obesity and knee osteoarthritis. Lilly release via PR Newswire. Sponsor topline

  3. TRIUMPH-1 topline

    Lilly announced results from its main phase 3 obesity trial. Lilly release (BioSpace copy of the PR Newswire text). Sponsor topline

  4. TRIUMPH-2 and TRIUMPH-3 toplines, and a submission plan

    Lilly announced results in obesity with type 2 diabetes and in severe obesity with cardiovascular disease. The same release says Lilly is still completing the manufacturing (CMC) data package needed for the Biologics License Application and "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval." Lilly release (BioSpace copy).

  5. TRIUMPH-1 published in a journal

    "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity," N Engl J Med, online 2026-09-29, print issue 2026-11-05. DOI 10.1056/NEJMoa2604169. Peer reviewed Funded by Eli Lilly.

  6. TRIUMPH-4 and TRIUMPH-1-OA published in a journal

    "Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity," N Engl J Med. DOI 10.1056/NEJMoa2610676. Peer reviewed Funded by Eli Lilly.

  7. Not announced

    FDA acceptance, review designation, advisory committee, decision

    None of these has a public date. Estimates of an approval date on other websites are guesses, not company or FDA statements.

What to watch for

This is a summary of what the FDA has said, not legal advice.

Side effects from an unapproved product. If you have a bad reaction to any product, get medical care first. You can also report it to the FDA through MedWatch.

The only lawful, supervised way to receive retatrutide today is by taking part in a registered clinical trial. See official study records and what "recruiting" means. This site does not recommend joining or avoiding any study; that is a decision to make with a clinician.

Frequently asked questions

Is retatrutide FDA approved?

No. It is investigational. FDA material current as of 2026-10-01 says retatrutide has not been found safe and effective for any condition.

When will retatrutide be approved?

No date exists. Eli Lilly said on 2026-07-23 that it plans to submit retatrutide to the FDA in the first quarter of 2027. After a submission the FDA decides whether to accept and review it. No FDA decision date has been announced.

Is it legal to buy "research" retatrutide?

FDA has stated that retatrutide cannot be used in compounding under federal law and has warned sellers whose products were labeled "for research purposes" or "not for human consumption" but were sold for human use. FDA says such products are of unknown quality and may be harmful. This site does not give legal advice.

Sources used on this page

  • FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss," content current as of 2026-10-01.
  • FDA warning letter reference 735067, issued 2026-08-24 by the Center for Drug Evaluation and Research.
  • Eli Lilly and Company releases dated 2025-12-11, 2026-05-21 and 2026-07-23.
  • New England Journal of Medicine articles above, DOIs as listed.

Last checked . Independent summary of published sources. Editorial policy and corrections